RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1229 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a price target of $1229.
June 24, 2024 | 2:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Regeneron Pharmaceuticals and maintained a price target of $1229, indicating continued confidence in the company's performance.
The reiteration of an Outperform rating and a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100